A researcher who received a lifetime funding ban for misconduct from a Canadian agency has logged her third retraction, after a re-analysis of her work unveiled “serious inconsistencies.”
In July, the Canadian Institutes of Health Research (CIHR) released a report about Sophie Jamal, following an investigation by her former employer, The Women’s College Hospital in Toronto, Canada. The probe concluded that Jamal had manipulated data, which resulted in her being banned from CIHR funding for life, and the retraction of a study in The Journal of the American Medical Association.
After that retraction, researchers that made up the the Canadian Multicentre Osteoporosis Study Group (CaMos) decided to take a second look at Jamal’s work. In August, we reported on a retraction that came out of that examination, in the American Journal of Kidney Diseases (AJKD). At the time, a senior researcher from the group told us the group had also requested another journal retract a CaMos paper.
The research involves DiaPep277, which, as Josh Levy explained here in September, “would cause the immune system to stop attacking beta cells,” the cells in the pancreas that produce insulin. But Hyperion Therapeutics, which had acquired DiaPep277 developer Andromeda Biotech in June, announced in September that it had
uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result.
Here’s one retraction, from Diabetes Care, for “The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients With Type 2 Diabetes: The Shiga Microalbuminuria Reduction Trial (SMART):”